摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氯-4-氟三氟甲苯 | 94444-58-3

中文名称
2-氯-4-氟三氟甲苯
中文别名
2-氯-4-氟-1-三氟甲苯
英文名称
2-chloro-4-fluoro-1-(trifluoromethyl)benzene
英文别名
2-chloro-4-fluorobenzotrifluoride
2-氯-4-氟三氟甲苯化学式
CAS
94444-58-3
化学式
C7H3ClF4
mdl
MFCD03412197
分子量
198.547
InChiKey
UHHZGIHGBLCIJM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    -42°C
  • 沸点:
    102-105°C
  • 密度:
    2,9 g/cm3
  • 闪点:
    50℃

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.142
  • 拓扑面积:
    0
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S26,S36/37/39
  • 危险类别码:
    R36/37/38
  • 海关编码:
    2903999090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:1ad8c552246e62e08bc128cd8c93c142
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Chloro-4-fluoro-1-trifluoromethylbenzene
Synonyms: 2-Chloro-4-fluorobenzotrifluoride

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-4-fluoro-1-trifluoromethylbenzene
CAS number: 94444-58-3

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H3ClF4
Molecular weight: 198.5

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-氯-4-氟三氟甲苯四丁基氟化铵 、 sodium hydride 作用下, 以 四氢呋喃1,4-二氧六环 、 mineral oil 为溶剂, 反应 36.0h, 生成 3-氯-4-三氟甲基苯酚
    参考文献:
    名称:
    Chemical Compounds
    摘要:
    该发明涉及磺胺类衍生物,它们在医学上的应用,含有它们的组合物,用于它们的制备方法以及用于这些方法的中间体。更具体地,该发明涉及一种新的磺胺类Nav1.7抑制剂,其化学式为(I):或其药用可接受的盐,其中Ar1、X、R1、R2、R3、R4和R5如描述中所定义。Nav1.7抑制剂在治疗各种疾病,特别是疼痛方面具有潜在的用途。
    公开号:
    US20120010207A1
  • 作为产物:
    描述:
    2-氯-4-硝基三氟甲苯 在 potassium fluoride 、 四苯基溴化膦 作用下, 以 二甲基亚砜 为溶剂, 反应 5.0h, 以48%的产率得到2-氯-4-氟三氟甲苯
    参考文献:
    名称:
    Selective fluorodenitration of chloronitroaromatics
    摘要:
    Nucleophilic fluorination of chloronitrobenzenes shows a strong bias for fluorodenitration rather than halogen exchange.
    DOI:
    10.1016/s0022-1139(00)80394-2
点击查看最新优质反应信息

文献信息

  • [EN] ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS<br/>[FR] INHIBITEURS ALPHA-D-GALACTOSIDE DE GALECTINES
    申请人:GALECTO BIOTECH AB
    公开号:WO2016120403A1
    公开(公告)日:2016-08-04
    The present invention relates to a compound of the general formula (1). wherein the pyranose ring is a-D-galactopyranose, A is selected from The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns compounds for use in a method of treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    本发明涉及一般式(1)的化合物。其中吡喃糖环为α-D-半乳糖,A选自。该式(1)化合物适用于治疗与在哺乳动物,如人类中的一个配体结合相关的疾病的方法。此外,本发明涉及用于治疗与在哺乳动物,如人类中的一个配体结合相关的疾病的方法的化合物。
  • [EN] SEMICARBAZIDE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES DE SEMI-CARBAZIDE COMME INHIBITEURS DE KINASE
    申请人:MERCK PATENT GMBH
    公开号:WO2005082853A1
    公开(公告)日:2005-09-09
    The present invention relates to semicarbazide derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    本发明涉及公式I的半尿素衍生物,公式I化合物作为一种或多种激酶的抑制剂的用途,公式I化合物用于制备药物组合物以及包括向患者施用所述药物组合物的治疗方法。
  • [EN] SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES<br/>[FR] ACIDES SUBSTITUES POUR LE TRAITEMENT DE MALADIES RESPIRATOIRES
    申请人:ASTRAZENECA AB
    公开号:WO2006005909A1
    公开(公告)日:2006-01-19
    The invention relates to substituted acids of formula (I), where T,W,X,Y,Z,R1 and R2 as defined in the claims, as useful pharmaceutical compounds for treating asthma and rhinitis, pharmaceutical compositions containing them, and a processes for their preparation.
    该发明涉及公式(I)中T、W、X、Y、Z、R1和R2如权利要求中定义的取代酸,作为治疗哮喘和鼻炎的有用药物化合物,包含它们的药物组合物,以及它们的制备方法。
  • Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease
    作者:Daniel W. Kneller、Hui Li、Stephanie Galanie、Gwyndalyn Phillips、Audrey Labbé、Kevin L. Weiss、Qiu Zhang、Mark A. Arnould、Austin Clyde、Heng Ma、Arvind Ramanathan、Colleen B. Jonsson、Martha S. Head、Leighton Coates、John M. Louis、Peter V. Bonnesen、Andrey Kovalevsky
    DOI:10.1021/acs.jmedchem.1c01475
    日期:2021.12.9
    acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins is crucial to battle coronavirus disease 2019 (COVID-19). SARS-CoV-2 main protease (Mpro) is an established drug target for the design of protease inhibitors. We performed a structure–activity relationship (SAR) study of noncovalent compounds that bind in the enzyme’s substrate-binding subsites S1 and S2, revealing structural, electronic
    开发针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 蛋白的小分子抗病毒药物对于对抗 2019 年冠状病毒病 (COVID-19) 至关重要。 SARS-CoV-2 主要蛋白酶 (M pro ) 是设计蛋白酶抑制剂的既定药物靶点。我们对与酶的底物结合亚位点 S1 和 S2 结合的非共价化合物进行了构效关系 (SAR) 研究,揭示了这些位点的结构、电子和静电决定因素。该研究以 M pro与 Mcule-5948770040(化合物1 )复合的 X 射线/中子结构为指导,其中质子化状态直接可视化。采用虚拟现实辅助结构分析和小分子构建来生成1的类似物。体外酶抑制测定和室温 X 射线结构证明了化学修饰对 M pro抑制的影响,表明(1)维持抑制剂 P1 基团的正确几何形状对于保留与质子化的 His163 的氢键至关重要; (2)优选带正电荷的接头; (3) 亚位点 S2 更喜欢体积较小的适度电负性基团。
  • Chemical Compounds
    申请人:Bell Andrew Simon
    公开号:US20120010207A1
    公开(公告)日:2012-01-12
    The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Ar 1 , X, R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.
    该发明涉及磺胺类衍生物,它们在医学上的应用,含有它们的组合物,用于它们的制备方法以及用于这些方法的中间体。更具体地,该发明涉及一种新的磺胺类Nav1.7抑制剂,其化学式为(I):或其药用可接受的盐,其中Ar1、X、R1、R2、R3、R4和R5如描述中所定义。Nav1.7抑制剂在治疗各种疾病,特别是疼痛方面具有潜在的用途。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐